SEOUL, April 6 (Reuters) - Celltrion Inc's U.S. Food and Drug Administration-approved biosimilar version of Johnson & Johnson's drug Remicade is expected to be priced about 20 to 30 percent lower than Remicade in the U.S. market, Celltrion's chief executive said on Wednesday.
Read more
No comments:
Post a Comment